International Journal of Infectious Diseases最新文献

{"title":"Mycotic aneurysm due to Magnusiomyces capitatus complicating a second liver transplant in a colonized patient","authors":"Charles Gibert ,&nbsp;Marie Wan ,&nbsp;Matthieu Arsicot ,&nbsp;Ugo Huvelle ,&nbsp;Thomas Penhoat ,&nbsp;Yatrika Koumar ,&nbsp;Charline Miossec ,&nbsp;Florence Persat ,&nbsp;Florent Valour ,&nbsp;Jean Menotti ,&nbsp;Pauline Tirard-Collet","doi":"10.1016/j.ijid.2024.107370","DOIUrl":"10.1016/j.ijid.2024.107370","url":null,"abstract":"<div><div>This report presents an extremely rare case of a fungal mycotic aneurysm due to <em>Magnusiomyces capitatus</em> in a 51-year-old woman who is immunocompromised. The diagnosis was based on multiple computed tomography scans and the identification of the pathogen via sequencing of the internal transcribed spacer region. Long-term treatment with caspofungin for previous candidemia likely promoted the dissemination of this intrinsically echinocandin-resistant fungus from colonization sites in the lungs and rectal area. Long-term suppressive antifungal therapy with voriconazole and subsequently with posaconazole, combined with multiple surgical procedures, led to an improvement in the patient's condition. This case highlights the importance of considering a patient's comprehensive microbiological history and reassessing antimicrobial therapy in cases of nonimprovement or relapse.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"Article 107370"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventing ventilator-associated pneumonia: A position paper of the International Society for Infectious Diseases, 2024 update","authors":"Victor Daniel Rosenthal ,&nbsp;Ziad A. Memish ,&nbsp;Gonzalo Bearman","doi":"10.1016/j.ijid.2024.107305","DOIUrl":"10.1016/j.ijid.2024.107305","url":null,"abstract":"<div><h3>Objectives</h3><div>This review by a panel of experts convened by the International Society for Infectious Diseases aims to consolidate current recommendations for preventing ventilator-associated pneumonia (VAP). It provides insights into VAP rates, the attributable extra length of stay, costs, mortality, and risk factors in high-income and low- and middle-income countries (LMICs).</div></div><div><h3>Methods</h3><div>A comprehensive review of existing recommendations and evidence-based strategies for preventing VAP was conducted. The expert panel analyzed data on VAP incidence, associated healthcare burdens, and risk factors across different economic settings to formulate applicable preventive measures.</div></div><div><h3>Results</h3><div>The review identifies significant differences in VAP rates, healthcare costs, extra length of hospital stay, and mortality between high-income and LMICs. Evidence-based strategies for preventing VAP were highlighted, demonstrating their effectiveness across different healthcare settings.</div></div><div><h3>Conclusion</h3><div>The recommendations and insights provided in this position paper aim to guide healthcare professionals in effectively preventing VAP. The adoption of evidence-based preventive strategies can potentially reduce VAP rates, and associated costs, and improve patient outcomes in both high-income and LMICs.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"Article 107305"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventing catheter-associated urinary tract infections: A position paper of the International Society for Infectious Diseases, 2024 update","authors":"Victor Daniel Rosenthal ,&nbsp;Ziad A. Memish ,&nbsp;Emanuele Nicastri ,&nbsp;Sebastiano Leone ,&nbsp;Gonzalo Bearman","doi":"10.1016/j.ijid.2024.107304","DOIUrl":"10.1016/j.ijid.2024.107304","url":null,"abstract":"<div><h3>Objectives</h3><div>This review, conducted by a panel of experts assembled by the International Society for Infectious Diseases, seeks to consolidate the latest recommendations for preventing catheter-associated urinary tract infections (CAUTIs). It offers insights into CAUTI rates and the associated extended hospital stays, costs, mortality, and risk factors across high- and low- to middle-income countries.</div></div><div><h3>Methods</h3><div>An in-depth review of current recommendations and evidence-based strategies for CAUTI prevention was undertaken. To develop practical preventive measures, the expert panel examined data on CAUTI incidence, related health care impacts, and risk factors across various economic contexts.</div></div><div><h3>Results</h3><div>The review highlights notable differences in CAUTI rates, health care costs, extended hospital stays, and mortality between high- and low- to middle-income countries. It emphasizes evidence-based strategies for CAUTI prevention, demonstrating their effectiveness across diverse health care environments.</div></div><div><h3>Conclusions</h3><div>This position paper offers recommendations and insights intended to assist health care professionals in effectively preventing CAUTIs. Implementing evidence-based preventive strategies has the potential to lower CAUTI rates, reduce related costs, and enhance patient outcomes in high- and low- to middle-income countries.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"Article 107304"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16/18 infections and CIN2+ in women: a systematic review and network meta-analysis","authors":"Haiyue Wu ,&nbsp;Lucia Li ,&nbsp;Kun Fu ,&nbsp;YuFei Shen ,&nbsp;Yingnan Lu ,&nbsp;Zexi Liao ,&nbsp;Yingzhen Liu ,&nbsp;Wenting Zha ,&nbsp;Lisha Wu ,&nbsp;Yu Zhang","doi":"10.1016/j.ijid.2024.107363","DOIUrl":"10.1016/j.ijid.2024.107363","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the efficacy of 2-valent, 4-valent and 9-valent HPV vaccination in preventing persistent HPV infections and cervical intraepithelial neoplasia grade 2 or higher (CIN2+) lesions among women with different infection statuses at baseline.</div></div><div><h3>Methods</h3><div>PubMed, Web of Science, Cochrane, Embase and ClinicalTrials.gov were searched from their inception to March 2024. Randomized controlled trials (RCTs) and post hoc analyses of RCTs reporting the risk of persistent HPV infections and CIN2+ among vaccinated women were included. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to summarize the intervention effects.</div></div><div><h3>Results</h3><div>Eighteen RCTs and one post hoc analysis of RCTs were included. In the according-to-protocol (ATP) cohorts, the 4-valent vaccine was the most effective against HPV16/18-related persistent infections and CIN2+ (6-month persistent infections (6mPIs): OR 0.05, 95% CI [0.02, 0.15]; 12-month persistent infections (12mPIs): OR 0.02, 95% CI [0.00, 0.18]; CIN2+: OR 0.03 95% CI [0.01, 0.17]). For the total vaccination cohorts (TVCs), the 2-valent vaccine was most effective against HPV16/18-related 12mPIs and CIN2+ (12mPIs: OR 0.15, 95% CI [0.04, 0.63]; CIN2+: OR 0.52 95% CI [0.32, 0.87]), whereas the 4-valent vaccine was most effective against HPV16/18-related 6mPIs (OR 0.08, 95% CI [0.02, 0.28]).</div></div><div><h3>Conclusions</h3><div>Vaccination against HPV can significantly reduce the risk of persistent HPV16/18-related infections and CIN2+, regardless of the HPV infection prevaccination. In addition to 4- and 9-valent vaccines, 2-valent vaccines could also provide satisfactory protection against persistent HPV16/18-related infections and CIN2+, especially over the long term, and may constitute an alternative for government-led vaccination programs in developing countries.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"Article 107363"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and risk factors for mortality in clostridial bacteremia in Japan: A retrospective multicenter observational study","authors":"Aiko Okazaki ,&nbsp;Shu Okugawa ,&nbsp;Tatsuya Kobayashi ,&nbsp;Miki Kawada ,&nbsp;Kyotaro Kawase ,&nbsp;Shin Nakayama ,&nbsp;Yoshitaka Wakabayashi ,&nbsp;Takatoshi Kitazawa ,&nbsp;Riko Takezawa ,&nbsp;Keita Tatsuno ,&nbsp;Saho Koyano ,&nbsp;Yoshimi Higurashi ,&nbsp;Mahoko Ikeda ,&nbsp;Sohei Harada ,&nbsp;Takeya Tsutsumi","doi":"10.1016/j.ijid.2024.107358","DOIUrl":"10.1016/j.ijid.2024.107358","url":null,"abstract":"<div><h3>Objectives</h3><div><em>Clostridium</em> species are ubiquitous in nature and commonly cause infections, including bacteremia. <em>C. perfringens</em> is often the causative species, while the epidemiology of other clostridial species remains unclear. This study aimed to examine the epidemiology and risk factors for mortality among patients with clostridial bacteremia in Japan.</div></div><div><h3>Methods</h3><div>This multicenter, retrospective cohort study analyzed patients with <em>Clostridium</em> spp. in blood cultures from four tertiary hospitals in Japan. Data on demographics, underlying conditions, clinical and laboratory values, and in-hospital mortality were included. Multivariate logistic regression analysis identified independent risk factors for in-hospital mortality.</div></div><div><h3>Results</h3><div>Of 349 patients with <em>Clostridium</em> spp. in blood cultures, 278 (79.7%) had clinically significant clostridial bacteremia: <em>C. perfringens</em> was the most common species (52.9%), followed by <em>C. ramosum</em> (9.7%) and <em>C. clostridioforme</em> (4.3%). The median patient age was 77 years, and 61.9% were male. The in-hospital mortality rate was 25.9%, with 34.7% of deaths occurring within 3 days of the date of the positive blood culture. Independent risk factors for mortality were hepato-pancreato-biliary malignancy, chronic heart failure, acute renal failure, Pitt bacteremia score, and pneumonia.</div></div><div><h3>Conclusions</h3><div>Mortality from clostridial bacteremia is high, particularly among patients with pneumonia, comorbidities, or severe acute conditions. To improve mortality, early-stage treatment strategies are needed.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"Article 107358"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccination and cerebral small vessel disease progression—A prospective cohort study","authors":"Yiu Ming Bonaventure Ip ,&nbsp;Sangqi Pang ,&nbsp;Alan Yao ,&nbsp;Lucas Lau ,&nbsp;Anki Miu ,&nbsp;Katarina Chiu ,&nbsp;Ho Ko ,&nbsp;Andrew Kwok ,&nbsp;Helen Y Chan ,&nbsp;Sharon Lee ,&nbsp;Howard Chan ,&nbsp;Trista Hung ,&nbsp;Bonnie Lam ,&nbsp;Vincent Hui ,&nbsp;Haipeng Li ,&nbsp;Lin Shi ,&nbsp;Jill Abrigo ,&nbsp;Xinyi Leng ,&nbsp;Yannie Soo ,&nbsp;Sze Ho Ma ,&nbsp;Thomas W Leung","doi":"10.1016/j.ijid.2024.107324","DOIUrl":"10.1016/j.ijid.2024.107324","url":null,"abstract":"<div><h3>Objectives</h3><div>The association between SARS-CoV-2 spike protein and cerebrovascular diseases raised a concern of cerebrovascular safety of COVID-19 vaccines. We aimed to determine the risk of radiologic cerebral small vessel disease (cSVD) progression with BNT162b2 and CoronaVac.</div></div><div><h3>Methods</h3><div>In this community-based prospective cohort study, community-dwelling subjects underwent brain magnetic resonance imaging (MRI) before and 4 months after vaccination with BNT162b2 or CoronaVac. Unvaccinated subjects received serial brain MRI over a comparable interval. The primary outcome was progression of a composite of six standard cSVD biomarkers. We compared the risk of cSVD progression between vaccinated and unvaccinated subjects and identified predictors of primary outcome within each vaccine subgroup.</div></div><div><h3>Results</h3><div>Of the 415 subjects recruited, 190 received BNT162b2, 152 received CoronaVac, and 73 remained unvaccinated. A total of 60 (14.4%) had COVID-19 infection before follow-up MRI, and 109 (26.3%) developed the primary outcome. Neither BNT162b2 (adjusted odds ratio [aOR] 0.61, 95% confidence interval [CI] 0.30-1.26, <em>P</em> = 0.179) nor CoronaVac (aOR 0.71, 95% CI 0.34-1.47, <em>P</em> = 0.349) was associated with cSVD progression. Among the BNT162b2 recipients, a higher surrogate virus neutralization test was associated (aOR 0.97, 95% CI 0.95-0.99, <em>P</em> = 0.002) with a lower risk of cSVD progression.</div></div><div><h3>Conclusions</h3><div>BNT162b2 and CoronaVac did not increase cSVD burden in community-dwelling citizens. The association between surrogate virus neutralization test and cSVD progression among BNT162b2 recipients requires further investigation.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"Article 107324"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of adjunctive eravacycline for severe and fulminant Clostridioides difficile infection","authors":"Christen J. Arena ,&nbsp;Rachel M. Kenney ,&nbsp;Mayur Ramesh ,&nbsp;Susan L. Davis ,&nbsp;Michael P. Veve","doi":"10.1016/j.ijid.2024.107314","DOIUrl":"10.1016/j.ijid.2024.107314","url":null,"abstract":"<div><h3>Objectives</h3><div>To characterize eravacycline (ERV) treatment for severe or fulminant <em>Clostridioides difficile</em> infection (CDI) and describe patient outcomes.</div></div><div><h3>Methods</h3><div>This was an institutional review board–approved, cross-sectional study of hospitalized adult patients with CDI who received adjunctive ERV with standard-of-care antibiotics for CDI from January 2019 to December 2023 at a five-hospital health system. Patients were included if they received ERV with standard-of-care antibiotics for ≥24 hours for severe or fulminant CDI. Patients with a history colectomy or with non-CDI ERV indications were excluded. The primary outcome was the proportion of patients that required colectomy due to <em>C. difficile;</em> secondary outcome was all-cause mortality at 30 days.</div></div><div><h3>Results</h3><div>Seventy-five patients were included: 25 (33%) had severe and 50 (67%) fulminant CDI and 23 (31%) had refractory severe/fulminant CDI. Patients receiving ERV were frequently immunocompromised (30, 40%) and required treatment in an intensive care unit (46, 61%). Eleven (14.7%) patients required colectomy within 30 days of adjunctive ERV; 28 (37%) patients died at 30-days.</div></div><div><h3>Conclusions</h3><div>ERV may be useful as a potential adjunctive therapy for severe or fulminant CDI. Patients receiving ERV often were immunocompromised and had fulminant disease with critical illness. Future comparative studies are needed to evaluate the impact of adjunctive ERV for CDI.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"Article 107314"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of adherence counseling incorporating a point of care urine tenofovir assay on virologic suppression among individuals failing tenofovir-lamivudine-dolutegravir: A pre-post intervention study","authors":"Leonard Bikinesi ,&nbsp;Matthew A. Spinelli ,&nbsp;Ntombizodwa Nyoni ,&nbsp;Daniella Mouton ,&nbsp;Assegid Mengistu ,&nbsp;Jacques Kamangu ,&nbsp;Iyaloo Konstantinus ,&nbsp;Pearl Kalimugogo ,&nbsp;Gram Mutandi ,&nbsp;Fekir Negussie ,&nbsp;Guohong Wang ,&nbsp;Susie Welty ,&nbsp;Willi McFarland ,&nbsp;R. Suzanne Beard ,&nbsp;Jessica Haberer ,&nbsp;Suzanne McCluskey ,&nbsp;Monica Gandhi ,&nbsp;Steven Y. Hong","doi":"10.1016/j.ijid.2024.107328","DOIUrl":"10.1016/j.ijid.2024.107328","url":null,"abstract":"<div><h3>Objectives</h3><div>To examine if point-of-care (POC) urine tenofovir testing-informed counseling could be used to improve virologic suppression (VS) among participants with virologic failure (VF) after ≥1 prior round of enhanced adherence counseling (EAC).</div></div><div><h3>Methods</h3><div>Participants were enrolled from 42 clinics across Namibia. At each monthly medication pick-up, participants completed the POC urine test and received EAC informed by this testing (EAC+). If VS was not achieved after 3 months of EAC+, up to 3 additional rounds of EAC+ were provided, with resistance testing at month (M)9.</div></div><div><h3>Results</h3><div>Of 310 potentially eligible participants across 42 clinics in Namibia, we enrolled 211 participants with VF (median age 33 years, 61% female); 195 reached M3 defined as receiving EAC+ and follow-up viral load testing; 169 achieved VS within M3 (87%, <em>P</em> &lt; 0^.001) and 97% by M9 (181/186) compared to 40% (22/55) prior to the intervention (<em>P</em> &lt; 0.001). Resistance testing was performed in five remaining participants with VF at M9, of whom 1/5 (20%) developed dolutegravir resistance.</div></div><div><h3>Conclusion</h3><div>The urine tenofovir assay when incorporated into adherence counseling has potential to be a cost-effective intervention among participants failing tenofovir-based regimens, increasing VS to 97% in those failing Tenofovir-Lamivudine-Dolutegravir. Encouraging results of this pre-post intervention will be rigorously tested in a randomized trial.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"Article 107328"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergence of cefiderocol resistance during therapy in NDM-5–producing Klebsiella pneumoniae isolates harboring siderophore receptors mutations","authors":"Luc Deroche ,&nbsp;Albane Rozenholc ,&nbsp;François Arrivé ,&nbsp;Jean-Philippe Martellosio ,&nbsp;Gwenaël Le Moal ,&nbsp;Arnaud W. Thille ,&nbsp;Olivier Barraud ,&nbsp;Sandrine Marchand ,&nbsp;Julien M. Buyck","doi":"10.1016/j.ijid.2024.107321","DOIUrl":"10.1016/j.ijid.2024.107321","url":null,"abstract":"<div><div>Cefiderocol, a siderophore-conjugated cephalosporine, is a promising drug used to treat infection with carbapenem-resistant gram-negative bacteria. Here, we report a case of pneumonia induced by multiple gram-negative pathogens, including a carbapenem-resistant <em>Klebsiella pneumoniae</em> developing cefiderocol resistance within 32 days of cefiderocol therapy. Whole genome sequencing of three consecutive <em>K. pneumoniae</em> isolates revealed that the bacteria were isogenic and were carrying several broad-spectrum β-lactamases (<em>bla</em>_NDM5 and <em>bla</em>_CTX-M-15). Two isolates with elevated minimum inhibitory concentration against cefiderocol harbored mutations in genes encoding siderophore: one in the <em>cirA</em> gene and one in both the <em>cirA</em> and the <em>fiu</em> genes. The combination of a metallo-β-lactamase background and mutations in siderophore receptors was associated with phenotypic resistance to cefiderocol.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"Article 107321"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of bone destruction in patients with TALAROMYCES MARNEFFEI infection: A systematic review and meta-analysis","authors":"Junhong Zhou ,&nbsp;Deshuang Xi ,&nbsp;Yilin Teng ,&nbsp;Shaohui Zong ,&nbsp;Gaofeng Zeng","doi":"10.1016/j.ijid.2024.107359","DOIUrl":"10.1016/j.ijid.2024.107359","url":null,"abstract":"<div><h3>Objectives</h3><div>This systematic review and meta-analysis aimed to evaluate the prevalence of bone destruction in patients with Talaromyces marneffei infection, examine distribution patterns of bone lesions, and assess differences between HIV-positive and HIV-negative patients.</div></div><div><h3>Methods</h3><div>Following PRISMA guidelines, 15 studies involving 839 patients were analyzed. Random-effects meta-analysis was performed to estimate prevalence and odds ratios. Study quality was assessed using ROBINS-I.</div></div><div><h3>Results</h3><div>The overall prevalence of bone destruction was 18% (95% CI: 10-27%). HIV-negative patients showed significantly higher odds of bone destruction (OR: 0.09, 95% CI: 0.02-0.37%). Bone lesions were widely distributed, with osseous involvement (45.7-71.4%) more prevalent than articular (7.1-66.7%). The skull, ribs, and lumbar vertebrae were commonly affected.</div></div><div><h3>Conclusion</h3><div>Bone destruction is a significant complication in TM infection, particularly in HIV-negative patients. The diverse anatomical distribution emphasizes the need for comprehensive skeletal assessment in suspected cases.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"Article 107359"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}